When the Treatment Becomes the Disease: Rituximab-Induced Crohn Disease in PR3+ ANCA-Associated Vasculitis (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #TH-PO0848; Pres time: Oct 22, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "She failed steroids and was treated with Upadacitinib 45 mg daily. New GI symptoms in patients on Rituximab should not be reflexively attributed to infection or vasculitis flare. De novo IBD deserves a spot on the differential, and early recognition can change the treatment trajectory entirely."
ANCA Vasculitis • Crohn's disease • Gastroenterology • Gastrointestinal Disorder • Genetic Disorders • Immunology • Infectious Disease • Inflammation • Inflammatory Bowel Disease • Musculoskeletal Pain • Vasculitis
|
|
Bina Amin; Lauren Diane Goldbeck; Sydney Power; Koyal Jain
|